ArticleIndian dermatology online journal2026
Therapeutic Effectiveness of Narrowband-Ultraviolet B Phototherapy in Uremic Pruritus Patients with Chronic Kidney Disease Undergoing Hemodialysis - A Prospective Study.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUremic pruritus is a common, debilitating symptom experienced by chronic kidney disease (CKD) patients undergoing hemodialysis. AIM AND
objectiveThis study aimed to evaluate the therapeutic effectiveness of narrowband ultraviolet B (NB-UVB) phototherapy in managing uremic pruritus. PATIENTS AND
methodsThis descriptive study was conducted from April 2021 to October 2022 among 56 clinically diagnosed CKD patients with uremic pruritus, aged between 18 and 70 years, and undergoing hemodialysis. Patients received NB-UVB phototherapy twice weekly, with an initial dose of 300 mJ/cm² and increments of 10% per sitting. Treatment response was documented using a visual analogue scale (VAS), with a 50% reduction in pruritus considered an adequate therapeutic response.
resultsMean age of patients was 49.7 ± 5.6 years, with male predominance (58.9%). Mean duration of itching was 10.9 ± 4.9 months. The most common skin lesion was xerosis (67.8%). The mean VAS score reduced significantly from 8.48 at baseline to 4.76 at the end of week 8. A significant negative correlation was observed between UVB dose and VAS score at week 8, indicating that VAS score decreased with increasing UVB dose. Laboratory parameters before and after NB-UVB therapy revealed no significant differences. LIMITATIONS: This study has several limitations, including the absence of a control group and a small sample size (n = 56). Follow-up was limited to 8 weeks only. All patients had Fitzpatrick skin phototypes V or VI, limiting applicability to lighter-skinned populations. While a medication history was obtained, complete subclassification of all drugs was not performed. Systematic serological screening for autoimmune conditions was not conducted, and biopsy-proven CKD etiology was not available for all patients.
conclusionPhototherapy with NB-UVB light is effective in reducing pruritus among patients with CKD undergoing hemodialysis, with no significant side effects observed during the treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.